C
CNS Pharmaceuticals, Inc. (CNSP)
NCM – Real Time Price. Currency in USD
3.98
-0.17 (-4.14%)
At close: Jun 26, 2026, 4:00 PM EDT
3.98
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.98
-0.17 (-4.14%)
At close: Jun 26, 2026, 4:00 PM EDT
3.98
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $3.0M significantly exceed its total debt $232.4K, ensuring strong financial flexibility
Total current liabilities $4.6M surpass Total current assets $4.1M, signaling liquidity issues
Debt-to-equity ratio (3.3) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (-814.1x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$4.7M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.88 | 6.05 | 5.0 | |
| Quick ratio | 0.88 | 5.63 | 5.0 | |
| Debt to Equity | 3.29 | 0.30 | 2.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | -814.14 | -16.91 | 1.0 | |
| Weighted average score | 4.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -12K | -4K | -3K | -4K | -5K |
| Operating Income | -15M | -19M | -15M | -16M | -17M |
| Net Income | -15M | -19M | -15M | -16M | -16M |
| EBITDA | -15M | -19M | -15M | -16M | -17M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 96.26 | 5.5 |
| Next quarter | N/A | 95.31 | 5.5 |
| Current year | N/A | 95.38 | 5.5 |
| Next year | 22.67 | -0.61 | 5.5 |
| Weighted average score | 5.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 17.11 | -43.41 | -51.62 | 5.3 |
| Y/Y | 999 | -14.77 | 61.5 | 43.93 | 7.8 |
| 3y average | 999 | -2.96 | N/A | -11.89 | 3.3 |
| 5y average | 999 | -13.49 | 42.93 | -19.65 | 5.5 |
| Weighted average score | 5.5 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |